Evogene Ltd. — Foreign Filer Report 2021

Jul 1, 2021

6-K 1 zk2126249.htm 6-K Licensed to: company Document created using EDGARfilings PROfile 7.5.0.0 Copyright 1995 - 2021 Broadridge

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2021

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street

Park Rehovot P.O.B 4173

Ness Ziona 7414003, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

PROfilePageNumberReset%Num%2%%%

CONTENTS

Evogene Ltd., or the Company, reports changes in its management:

Mr. Lazer Bezdin has been appointed Chief Operating Officer, effective July 1, 2021. Mr. Bezdin brings more than 20 years of business experience, mainly in the pharmaceuticals and clean-tech industries. His experience includes 10 years in various roles in Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA). Immediately prior to joining the Company, he served as VP Sales & Business Development in Elcon Recycling, a subsidiary of Shikun & Binui Ltd. (TASE: SKBN).

In addition, Dr. Eyal Emmanuel has requested to reduce his management role as the Company’s Chief Scientific Officer, which he has held for over two years. Accordingly, effective July 1, 2021, Dr. Emmanuel will be appointed VP New Directions, on a part-time basis.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission, or SEC, File No. 333-253300), and Form S-8 (SEC File Nos. 333-193788, 333-201443 and 333-203856) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 1, 2021 EVOGENE LTD. (Registrant) By: /s/ Dorit Kreiner —————————————— Dorit Kreiner Chief Financial Officer

3